In this issue... Company features, market insight & Aggressive Portfolio III.
Testing times for Novacyt?
There is no disputing the fact that 2020 was a phenomenal year for AIM-listed Novacyt (338.5p). The company ended 2019 with a share price of 13p but it was able to move quickly to secure substantial revenues from Covid-19 related products and this saw net assets multiply in value within a few months. Potential investors must decide whether this was a one-off phenomenon or a platform from which the business can develop further.
In the year ended 31 December 2020 revenue was £277.2m versus £11.5m in 2019…
CONTINUED IN THE FULL NEWSLETTER CLICK TO READ.